Simcere Pharmaceutical Group (SCR) Misses Q1 EPS by 2c

Simcere Pharmaceutical Group (NYSE: SCR) reported Q1 EPS of $0.08, $0.02 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $77.4 million versus the consensus estimate of $84.31 million.

For earnings history and earnings-related data on Simcere Pharmaceutical Group (SCR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c